Table 1.
Comparison of Baseline Demographics, Clinical Parameters, and Medication Use Between Patients in the Warfarin and NOACs Groups
| Warfarin (n=30) | NOACs (n=98) | P Value | |
|---|---|---|---|
| Age, y | 64.9±8.9 | 62.2±9.4 | 0.111 |
| Male | 16 (53.3) | 65 (66.3) | 0.196 |
| Body mass index, kg/m2 | 23.7±5.7 | 23.2±3.0 | 0.236 |
| Paroxysmal atrial fibrillation | 22 (73.3) | 71 (72.4) | 0.924 |
| Duration of atrial fibrillation (months) | 64.1±94.3 | 47.5±63.6 | 0.582 |
| Hypertension | 19 (63.3) | 51 (52.0) | 0.277 |
| Age >75 y | 3 (10.0) | 11 (11.2) | 0.576 |
| Diabetes mellitus | 3 (10.0) | 14 (14.3) | 0.398 |
| Stroke | 3 (10.0) | 8 (8.2) | 0.500 |
| CHADS2‐VASc score | |||
| 0 | 4 (13.3) | 23 (23.5) | 0.234 |
| 1 | 5 (16.7) | 22 (22.4) | 0.497 |
| ≥2 | 21 (66.7) | 53 (54.1) | 0.122 |
| HAS‐BLED score | |||
| 0 | 10 (33.3) | 53 (54.1) | 0.047 |
| 1 | 13 (43.3) | 31 (31.6) | 0.238 |
| 2 | 7 (23.3) | 13 (13.3) | 0.149 |
| ≥3 | 1 (3.3) | 3 (3.1) | 0.661 |
| LAD, mm | 36.0±6.0 | 37.1±6.1 | 0.273 |
| LVEF | 63.2±4.9 | 63.0±5.8 | 0.770 |
| Hemoglobin, g/dLa | 13.9±1.6 | 14.1±1.5 | 0.443 |
| Platelet count, 103/μLa | 206.7±47.9 | 206.6±44.6 | 0.740 |
| eGFR, mL/min/1.73 m2 a | 70.2±12.7 | 78.2±58.8 | 0.469 |
| BNP, pg/mLa | 69.5±91.7 | 61.1±70.4 | 0.600 |
| Aspirin | 1 (3.3) | 7 (7.1) | 0.400 |
| CCB | 14 (46.7) | 37 (38.5) | 0.429 |
| β‐blockers | 11 (36.7) | 35 (35.7) | 0.924 |
| ARB/ACE‐I | 10 (33.3) | 40 (41.2) | 0.439 |
| Statins | 8 (26.7) | 27 (27.6) | 0.924 |
| Antiarrhythmic drug | 15 (50.0) | 70 (71.4) | 0.030 |
| PPI | 7 (23.3) | 24 (24.5) | 0.897 |
Data are mean±SD or n (%). ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, B‐type natriuretic peptide; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; NOACs, non–vitamin K antagonist oral anticoagulants; PPI, proton pump inhibitor.
a
Data of this parameter were at the point of admission.